Merck (MRK) and LaNova Medicines, a privately held clinical-stage biotechnology company, announced that Merck has entered into an exclusive ...

Merck & Co. licensed an experimental cancer antibody from a closely held Chinese company in a deal worth $588 million upfront ...

Merck & Co Inc. (MRK) and LaNova Medicines Ltd., a privately held clinical-stage biotechnology company Thursday said Merck has ...

In a move to safeguard the company’s dominant position in cancer, Merck said Thursday it will license a new cancer drug from ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

After-tax profit was 812 million euros compared with 740 million in the same period last year, Merck said Thursday. The ...

Merck has signed a licensing agreement worth up to $3.3 billion with Shanghai-based LaNova Medicines to develop, make and ...

On Tuesday, Merck & Co Inc (MRK) stock saw a decline, ending the day at $98.58 which represents a decrease of $-2.15 or -2.13% from the prior close of $100.73. The stock opened at $100.76 and touched ...

Merck KGaA on Thursday reported a gain of 11.9% in adjusted quarterly earnings, helped by cost-cutting measures and ...

Merck (NYSE: MRK) recently reported its Q3 results, with revenues and earnings exceeding the street estimates.

As the rollout of its recently launched pulmonary arterial hypertension (PAH) drug Winrevair ramps up, Merck is continuing ...

(Bloomberg) -- Merck KGaA posted earnings that topped estimates as its ... the mid-point and sales around the lower half of ...